Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Amyloidosis Clinical Trials

101 recruiting trials for Amyloidosis. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
101
Total Trials
101
Recruiting Now
6
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05283993

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed...

Sponsor: Peking University First HospitalEnrolling: 20001 location
RECRUITINGNCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and...

Sponsor: Sanguine BiosciencesEnrolling: 200001 location
RECRUITINGNCT06573723

Institutional Registry of Rare Diseases

The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD)....

Sponsor: Hospital Italiano de Buenos AiresEnrolling: 3801 location
RECRUITINGNCT06251778

NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue...

Sponsor: Paolo MilaniEnrolling: 2001 location
RECRUITINGNCT06539169

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in...

Sponsor: xCuresEnrolling: 10001 location
RECRUITINGNCT04265040

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research...

The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical...

Sponsor: University Hospital HeidelbergEnrolling: 20401 location
RECRUITINGPhase 1NCT06974877

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure...

Background: Anakinra is a drug used to treat people with certain diseases that affect their immune systems. Sometimes anakinra can cause proteins under the skin to clump...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 301 location
RECRUITINGPhase 2NCT07285044

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve...

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer...

Sponsor: Mayo ClinicEnrolling: 271 location
RECRUITINGPhase 2NCT07110844

Teclistamab-Daratumumab in AL Amyloidosis

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C)...

Sponsor: Suzanne Lentzsch, MDEnrolling: 251 location
RECRUITINGNCT06065852

National Registry of Rare Kidney Diseases

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research...

Sponsor: UK Kidney AssociationEnrolling: 350001 location
RECRUITINGNCT06528964

Proteinopathies Expression in Skin of Neurodegenerative Disorders

The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA...

Sponsor: Universidad Autonoma de San Luis PotosíEnrolling: 401 location
RECRUITINGNCT04579120

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).

Sponsor: Tammie L. S. Benzinger, MD, PhDEnrolling: 6501 location
RECRUITINGNCT04561518

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients *...

Sponsor: Alnylam PharmaceuticalsEnrolling: 150020 locations
RECRUITINGNCT06372301

Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy

The goal of this prospective clinical study is improve the diagnosis of Low-flow low-gradient aortic stenosis (LF/LG AS), in patients with co-existing wild-type transthyretin...

Sponsor: Steen Hvitfeldt PoulsenEnrolling: 241 location
RECRUITINGNCT07205666

The Eplontersen Pregnancy and Lactation Outcomes Study

The overall objective of this DPSS is to describe the occurrence of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects...

Sponsor: AstraZenecaEnrolling: 101 location
RECRUITINGPhase 1NCT04847453

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain...

This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain...

Sponsor: National Cancer Institute (NCI)Enrolling: 2416 locations
RECRUITINGNCT01137643

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future....

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 150001 location
RECRUITINGNCT07213297

Comprehensive Program for Hereditary Transthyretin Amyloidosis

The Comprehensive Program for Hereditary Transthyretin Amyloidosis describes a prospective observational study focused on understanding hereditary transthyretin amyloidosis...

Sponsor: Hospital de Alta Complejidad en RedEnrolling: 201 location
RECRUITINGPhase 1 / Phase 2NCT05774704

Curcumin and Retinal Study

To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and...

Sponsor: Texas Tech University Health Sciences CenterEnrolling: 601 location
RECRUITINGPhase 4NCT04667494

Ultrasound Therapy In Cardiac Amyloidosis

This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in myocardial blood...

Sponsor: Brigham and Women's HospitalEnrolling: 701 location
RECRUITINGPhase 2NCT06935162

Teclistamab in Previously Treated AL Amyloidosis

This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab

Sponsor: Peking Union Medical College HospitalEnrolling: 301 location
RECRUITINGPhase 2NCT06649695

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab

Sponsor: European Myeloma Network B.V.Enrolling: 3010 locations
RECRUITINGPhase 3NCT06128629

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Sponsor: Intellia TherapeuticsEnrolling: 120020 locations
RECRUITINGNCT03507257

Longitudinal Early-onset Alzheimer's Disease Study Protocol

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals...

Sponsor: Indiana UniversityEnrolling: 85020 locations
RECRUITINGPhase 1 / Phase 2NCT06097832

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).

Sponsor: Nexcella Inc.Enrolling: 4018 locations
RECRUITINGNCT06866912

Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis

observational epidemiological study of patients affected by systemic amyloidosis

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaEnrolling: 7501 location
RECRUITINGPhase 1NCT06372821

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease...

Sponsor: University College, LondonEnrolling: 102 locations
RECRUITINGNCT04849754

Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy

Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to...

Sponsor: GCS Ramsay Santé pour l'Enseignement et la RechercheEnrolling: 301 location
RECRUITINGNCT07435168

CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no...

Sponsor: Rigshospitalet, DenmarkEnrolling: 3001 location
RECRUITINGNCT04587648

Cardiac Amyloidosis in HFpEF

Heart failure with preserved ejection fraction (HFpEF) accounts for half of heart failure cases with heterogenous cause and variable presentations. The diagnosis of HFpEF required...

Sponsor: National Taiwan University HospitalEnrolling: 2501 location
RECRUITINGNCT06129656

Cardiac Amyloidosis Registry of University Hospital Leipzig

This is a clinical registry of patients with cardiac amyloidosis being treated at University Hospital Leipzig. The aim of the registry is to collect detailed information about...

Sponsor: University of LeipzigEnrolling: 5001 location
RECRUITINGNCT07112924

CCM OPEN HF Registry

The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.

Sponsor: Impulse DynamicsEnrolling: 55001 location
RECRUITINGPhase 3NCT06022939

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly...

This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and...

Sponsor: SWOG Cancer Research NetworkEnrolling: 33820 locations
RECRUITINGNCT06096675

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.

Sponsor: Wake Forest University Health SciencesEnrolling: 501 location
RECRUITINGPhase 1NCT05652335

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid...

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to...

Sponsor: Janssen Research & Development, LLCEnrolling: 18020 locations
RECRUITINGNCT07448935

One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS

By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains...

Sponsor: Fondazione IRCCS Policlinico San Matteo di PaviaEnrolling: 1001 location
RECRUITINGPhase 3NCT05508789

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is...

Sponsor: Eli Lilly and CompanyEnrolling: 150020 locations
RECRUITINGNCT07235462

A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid...

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in...

Sponsor: BayerEnrolling: 20001 location
RECRUITINGNCT04850105

A Non-interventional Cohort Safety Study of Patients With hATTR-PN

This is a prospective, non-interventional, Long-term, multinational cohort safety study of patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN). The...

Sponsor: Akcea TherapeuticsEnrolling: 24020 locations
RECRUITINGNCT07359690

Multimodal Analysis of Endomyocardial Biopsies

The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and...

Sponsor: University Hospital, EssenEnrolling: 2161 location
RECRUITINGNCT06757569

Radialis PET Imager for the Assessment of Neuritic Amyloid Plaque Burden

The standard or usual workup for cognitive impairment, including Alzheimer's Disease, may include brain amyloid PET with PET/CT or PET/MR imaging. Amyloid PET is the standard...

Sponsor: University Health Network, TorontoEnrolling: 1601 location
RECRUITINGNCT06083467

CW2IP2: Imaging and Diagnostic Assessments

This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and...

Sponsor: University of PennsylvaniaEnrolling: 941 location
RECRUITINGNCT02641145

Molecular Imaging of Primary Amyloid Cardiomyopathy

Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This project will develop a...

Sponsor: Brigham and Women's HospitalEnrolling: 1711 location
RECRUITINGNCT06400368

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.

Sponsor: NeuroVision ImagingEnrolling: 2001 location
RECRUITINGNCT02434393

Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project

The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is...

Sponsor: University of Southern CaliforniaEnrolling: 1202 locations
RECRUITINGPhase 2NCT07012993

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia...

Sponsor: Akiva MintzEnrolling: 2001 location
RECRUITINGNCT06345235

New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis

The development of cardiac amyloidosis is caused by the deposition of misfolded, insoluble proteins in the extracellular matrix of tissues. An important element of the clinical...

Sponsor: John Paul II Hospital, KrakowEnrolling: 1001 location
RECRUITINGNCT05950867

Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.

To investigate to what extent chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) is part of early non-cardiac manifestations of wild-type TTR...

Sponsor: Universitair Ziekenhuis BrusselEnrolling: 1501 location
RECRUITINGNCT04839003

A Registry of AL Amyloidosis (ReAL)

The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.

Sponsor: Fondazione IRCCS Policlinico San Matteo di PaviaEnrolling: 50001 location
RECRUITINGPhase 2NCT06420167

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain...

Sponsor: Barbara Ann Karmanos Cancer InstituteEnrolling: 201 location

Showing 50 of 101 trials.Search all Amyloidosis trials

Frequently Asked Questions

There are currently 101 clinical trials for Amyloidosis, with 101 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Amyloidosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 6 Phase 3 trials for Amyloidosis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.